Allicia Girvan


Authored Items

Anemia-Related Costs and Adverse Event Rates in Cancer Patients Who Do Not Respond to Erythropoietin Stimulating Agents

March 2013, Vol 4, No 3 - AVBCC 2013 3rd Annual Conference Abstracts

Background: While broadly utilized for treatment of anemia in cancer patients, treatment with erythropoietin stimulating agents (ESA) is not recommended in patients who fail to respond within 6-8 weeks.

Objective: This study examined the rate of adverse events (AE) and costs of continued exposure to ESAs in the absence of clinical response compared to those responding to ESA treatment.

[ Read More ]